Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
P.W. Wilson, R.B. D’Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel.
Prediction of coronary heart disease using risk factor categories.
Circulation, (1998), 97 pp. 1837-1847
[2.]
G. Assmann, P. Cullen, H. Schulte.
The Munster Heart Study (PROCAM). Results of follow-up at 8 years.
Eur Heart J, (1998), 19 pp. A2-A11
[3.]
A. Endo.
A gift from nature: the birth of the statins.
Nat Med, (2008), 14 pp. 1050-1052
[4.]
A. Endo.
The origin of the statins. 2004.
Atheroscler Suppl, (2004), 5 pp. 125-130
[5.]
E.S. Istvan, J. Deisenhofer.
Structural mechanism for statin inhibition of HMG-CoA reductase.
Science, (2001), 292 pp. 1160-1164
[6.]
L. Arnaboldi, A. Corsini.
Do structural differences in statins correlate with clinical efficacy?.
Curr Opin Lipidol, (2010), 21 pp. 298-304
[8.]
P.J. Neuvonen.
Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Curr Opin Invest Drugs, (2010), 11 pp. 323-332
[9.]
M. Schachter.
Chemical pharmacokinetic and pharmacodynamic properties of statins: an update.
Fundam Clin Pharmacol, (2005), 19 pp. 117-125
[10.]
Y. Shitara, Y. Sugiyama.
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Pharmacol Ther, (2006), 112 pp. 71-105
[11.]
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
[12.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
N Engl J Med, (1996), 335 pp. 1001-1009
[13.]
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
N Engl J Med, (1998), 339 pp. 1349-1357
[14.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
N Engl J Med, (1995), 333 pp. 1301-1307
[15.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA, (1998), 279 pp. 1615-1622
[16.]
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ, (2002), 324 pp. 71-86
[17.]
J.M. Hoeg, H.B. Brewer Jr.
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
JAMA, (1987), 258 pp. 3532-3536
[18.]
Cholesterol Treatment Trialists’ (CTT) Collaboration.
Efficacy and safety of intensive LDL-cholesterol-lowering therapy: A meta-analysis of data from 170 000 participants in 26 randomised trials.
Lancet, (2010), 376 pp. 1670-1681
[19.]
Study Of The Effectiveness Of Additional Reductions In Cholesterol And Homocysteine Search Collaborative G. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial.
Lancet, (2010), 376 pp. 1658-1669
[20.]
A.G. Olsson, J. Pears, J. McKellar, J. Mizan, A. Raza.
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Am J Cardiol, (2001), 88 pp. 504-508
[21.]
P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, et al.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Am J Cardiol, (2003), 92 pp. 152-160
[22.]
S.E. Nissen, S.J. Nicholls, I. Sipahi, P. Libby, J.S. Raichlen, C.M. Ballantyne, et al.
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
JAMA, (2006), 295 pp. 1556-1565
[23.]
J.R. Crouse 3rd, J.S. Raichlen, W.A. Riley, G.W. Evans, M.K. Palmer, D.H. O’Leary, et al.
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
JAMA, (2007), 297 pp. 1344-1353
[24.]
P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr, J.J. Kastelein, et al.
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Lancet, (2009), 373 pp. 1175-1182
[25.]
W. Koenig, P.M. Ridker.
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities.
Eur Heart J, (2011), 32 pp. 75-83
Copyright ©
2011. Sociedad Española de Cardiología